Flexion Therapeutics (NASDAQ:FLXN) has been assigned a $20.00 price target by investment analysts at Northland Securities in a research note issued on Tuesday, TipRanks reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Northland Securities’ price target points to a potential upside of 36.71% from the stock’s current price.
Several other brokerages have also recently issued reports on FLXN. BidaskClub upgraded shares of Flexion Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, September 4th. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. Finally, Zacks Investment Research raised Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Saturday, August 10th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $23.57.
NASDAQ:FLXN traded up $0.38 during mid-day trading on Tuesday, reaching $14.63. The company’s stock had a trading volume of 674,794 shares, compared to its average volume of 625,181. The company has a current ratio of 7.80, a quick ratio of 7.33 and a debt-to-equity ratio of 3.95. The stock has a market cap of $557.51 million, a P/E ratio of -3.26 and a beta of 1.23. The firm’s fifty day moving average price is $11.29 and its two-hundred day moving average price is $11.69. Flexion Therapeutics has a 12-month low of $8.76 and a 12-month high of $22.12.
In other Flexion Therapeutics news, insider Michael D. Clayman acquired 2,317 shares of the stock in a transaction dated Thursday, August 8th. The shares were purchased at an average price of $10.85 per share, for a total transaction of $25,139.45. Following the purchase, the insider now directly owns 72,249 shares of the company’s stock, valued at $783,901.65. The acquisition was disclosed in a filing with the SEC, which is available at this link. 16.01% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of FLXN. Quantamental Technologies LLC increased its stake in shares of Flexion Therapeutics by 310.1% in the 2nd quarter. Quantamental Technologies LLC now owns 3,449 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 2,608 shares in the last quarter. Aperio Group LLC bought a new stake in Flexion Therapeutics during the second quarter valued at about $46,000. Cutler Group LP grew its holdings in Flexion Therapeutics by 2,650.0% during the second quarter. Cutler Group LP now owns 5,500 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 5,300 shares during the period. BNP Paribas Arbitrage SA increased its position in Flexion Therapeutics by 53,692.3% in the first quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 6,980 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY purchased a new stake in Flexion Therapeutics in the second quarter worth about $123,000. 84.87% of the stock is owned by hedge funds and other institutional investors.
About Flexion Therapeutics
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Article: NASDAQ
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.